Page 10«..9101112..2030..»

Category : Nanomedicine

New Technology Developments in Healthcare Nanotechnology (Nanomedicine) Market to Grow during Forecast year 2020-2027 – re:Jerusalem

A new research document with the title GlobalHealthcare Nanotechnology (Nanomedicine) Market Report covering detailed analysis, Competitive landscape, forecast, and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions like North America, Europe and Asia-Pacific, South America, Middle East, and Africa. The report will help users gain market insights, future trends, and growth prospects for forecast to 2027.

Nanotechnology is among the most developing technologies in the present scenario. Nanotechnology is a term used when technical improvements occur at 0.1 to 100 nm scale. Nanomedicine is a field of nanotechnology that includes medicine development at the molecular level for prevention, diagnosis, treatment of diseases, and even redevelopment of tissues and organs. Hence, it aids in preserving and advances human health. Nanomedicine provides a remarkable solution for numerous life-threatening conditions such as Parkinson, Alzheimers, cancer, diabetes, blood-related diseases, lungs, orthopedic problems, neurological, and cardiovascular system.

Download Sample PDF Brochure of this research study at https://www.theinsightpartners.com/sample/TIPRE00007260/

Top Leading Companies

1. Sanofi2. Abbott3. Pfizer, Inc.4. CombiMatrix Corporation5. GE Healthcare6. Celgene Corporation7. Johnson & Johnson Services, Inc.8. Luminex Corporation9. Merck & Company, Inc.10. Nanosphere, Inc.

Our expert team is consistently working on updated data and information on the key players related business processes that value the market. For future strategies and predictions, we provide a special section regarding the COVID-19 situation.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Healthcare Nanotechnology (Nanomedicine) market which would mention How the Covid-19 is Affecting the Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions, and Proposal for Disposable Incontinence Products (DIPs) Players to fight Covid-19 Impact.

The researchers have analyzed the competitive advantages of those involved in the industries. While historical years were taken as 2020 2027, the base year for the study was 2020. Similarly, the report has given its projection for the year 2020 apart from the outlook for years 2020 2027.

The objective of the researchers is to find out the sales, value, and status of the Healthcare Nanotechnology (Nanomedicine) industry at the international levels. While the status covers the years of 2020 2027, the forecast is for the period 2020 2027 that will enable market players to not only plan but also execute strategies based on the market needs.

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for the Healthcare Nanotechnology (Nanomedicine) market. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving or preventing the growth of the industry. Researchers have also focused on individual growth trends besides their contribution to the overall market.

An outline of the regional analysis:

Healthcare Nanotechnology (Nanomedicine) Market recent innovations and major events.

Additional highlights of the Healthcare Nanotechnology (Nanomedicine) market report:

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 10+ companies.

Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPRE00007260/

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email:sales@theinsightpartners.com

Follow this link:
New Technology Developments in Healthcare Nanotechnology (Nanomedicine) Market to Grow during Forecast year 2020-2027 - re:Jerusalem

Recommendation and review posted by Alexandra Lee Anderson

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma – DocWire News

This article was originally published here

J Hematol Oncol. 2020 Nov 2;13(1):145. doi: 10.1186/s13045-020-00965-4.

ABSTRACT

BACKGROUND: Drug-loaded nanoparticles have established their benefits in the fight against multiple myeloma; however, ligand-targeted nanomedicine has yet to successfully translate to the clinic due to insufficient efficacies reported in preclinical studies.

METHODS: In this study, liposomal nanoparticles targeting multiple myeloma via CD38 or CD138 receptors are prepared from pre-synthesized, purified constituents to ensure increased consistency over standard synthetic methods. These nanoparticles are then tested both in vitro for uptake to cancer cells and in vivo for accumulation at the tumor site and uptake to tumor cells. Finally, drug-loaded nanoparticles are tested for long-term efficacy in a month-long in vivo study by tracking tumor size and mouse health.

RESULTS: The targeted nanoparticles are first optimized in vitro and show increased uptake and cytotoxicity over nontargeted nanoparticles, with CD138-targeting showing superior enhancement over CD38-targeted nanoparticles. However, biodistribution and tumor suppression studies established CD38-targeted nanoparticles to have significantly increased in vivo tumor accumulation, tumor cell uptake, and tumor suppression over both nontargeted and CD138-targeted nanoparticles due to the latters poor selectivity.

CONCLUSION: These results both highlight a promising cancer treatment option in CD38-targeted nanoparticles and emphasize that targeting success in vitro does not necessarily translate to success in vivo.

PMID:33138841 | DOI:10.1186/s13045-020-00965-4

Original post:
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma - DocWire News

Recommendation and review posted by Alexandra Lee Anderson

Noninvasive Molecular Imaging of the Enhanced Permeability and Retenti | IJN – Dove Medical Press

Betina Brresen,1 Anders Elias Hansen,2,3 Frederikke Petrine Fliedner,2 Jonas Rosager Henriksen,3 Dennis Ringkjbing Elema,3,4 Malene Brandt-Larsen,5 Lotte Kellemann Kristensen,2 6 Annemarie Thuri Kristensen,1 6 Thomas Lars Andresen,3 Andreas Kjr2,5

1Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C 1870, Denmark; 2Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N 2200, Denmark; 3DTU Health Technology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Lyngby, Kgs 2800, Denmark; 4DTU Health Technology, The Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Roskilde, 4000, Denmark; 5Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Copenhagen 2100, Denmark; 6Minerva Imaging, Copenhagen N 2200, Denmark

Correspondence: Andreas KjrCluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N 2200, DenmarkTel +45 35 32 75 04Fax +45 35 32 75 46Email akjaer@sund.ku.dk

Background: The accumulation of liposome encapsulated chemotherapy in solid cancers is dependent on the presence of the enhanced permeability and retention (EPR) effect. Positron emission tomography (PET) imaging with a liposome encapsulated radioisotope, such as liposome encapsulated Cu-64 (64Cu-liposome) may help to identify tumors with high liposome accumulation, and thereby stratify patients based on expected benefit from liposomal chemotherapy. However, intravenous administration of liposomes without a cytotoxic content is complicated by the accelerated blood clearance (ABC) phenomenon for succeeding therapeutic liposome dosing. Alternative markers for assessing the tumors EPR level are therefore warranted.Materials and Methods: To increase our understanding of EPR variations and to ultimately identify an alternative marker for the EPR effect, we investigated the correlation between 64Cu-liposome PET/CT (EPR effect) and 68Ga-RGD PET/CT (neoangiogenesis), 18F-FDG PET/CT (glycolysis), diffusion-weighted MRI (diffusivity) and interstitial fluid pressure in two experimental cancer models (CT26 and COLO 205).Results: 64Cu-liposome and 68Ga-RGD SUVmax displayed a significant moderate correlation, however, none of the other parameters evaluated displayed significant correlations. These results indicate that differences in neoangiogenesis may explain some EPR variability, however, as correlations were only moderate and not observed for SUVmean, 68Ga-RGD is probably insufficient to serve as a stand-alone surrogate marker for quantifying the EPR effect and stratifying patients.

Keywords: EPR effect, liposome, positron emission tomography, neoangiogenesis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the article here:
Noninvasive Molecular Imaging of the Enhanced Permeability and Retenti | IJN - Dove Medical Press

Recommendation and review posted by Alexandra Lee Anderson

Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Healthcare Nanotechnology (Nanomedicine) Market 2015 2021 – Eurowire

The Healthcare Nanotechnology (Nanomedicine) Market research report added by Market Study Report, LLC, provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and revenue forecasts, which further highlights its position in the industry, in tandem with the growth strategies adopted by leading industry players.

The Healthcare Nanotechnology (Nanomedicine) market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Healthcare Nanotechnology (Nanomedicine) market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

What pointers are covered in the Healthcare Nanotechnology (Nanomedicine) market research study?

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Healthcare Nanotechnology (Nanomedicine) market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Healthcare Nanotechnology (Nanomedicine) market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Healthcare Nanotechnology (Nanomedicine) market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Healthcare Nanotechnology (Nanomedicine) market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Some of the Major Highlights of TOC covers:

View original post here:
Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Healthcare Nanotechnology (Nanomedicine) Market 2015 2021 - Eurowire

Recommendation and review posted by Alexandra Lee Anderson

MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights – PharmiWeb.com

DGAP-News: MagForce AG / Key word(s): Half Year Results30.10.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights

- Very significant increase in European patient inquiries for NanoTherm therapy system for the treatment of glioblastomas

- U.S. focal prostate cancer treatment study: positive findings of Stage 1 confirmed during current Stage - positive treatment results also with the streamlined procedure

- Flexible commercialization models for focal cancer treatment centers in the U.S. in place

Berlin, Germany and Nevada, USA, October 30, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2020, ending on June 30, 2020, and operative highlights.

"During the first half of 2020, we have continued to pass several major milestones and have made significant progress both in Europe with our roll-out strategy and the U.S. with the start of the next stage in our pivotal clinical study for the focal ablation of intermediate risk prostate cancer. MagForce continues to cope with the ever-evolving situation around COVID-19, nevertheless I am steadfast in my belief that by pursuing a strategy of expansion with sustainable partnerships in Europe and providing NanoTherm therapy in the U.S. to patients suffering from prostate cancer, MagForce is well positioned for the future." commented Ben Lipps, CEO of MagForce AG and MagForce USA, Inc. "At the same time, MagForce today is in a better operational position than ever before in the company's history - the number of brain tumor treatments in Europe is increasing significantly and sustainably, the interest of clinics is really high, and in the U.S. our pivotal study for the focal treatment of prostate cancer proves that our therapy is achieving the very good treatment results we had hoped for."

Operative Highlights

Europe - Brain Cancer Treatment

In the first half of 2020 we received a very significant increase in patient inquiries for NanoTherm therapy - a strong indication of how convinced MagForce's partner clinics are of the therapeutic option and its use for the treatment of glioblastomas. It can be assumed that the number of treatments will continue to increase sustainably. The global opportunity for treating glioblastoma is approximately 160,000 patients per year - indicating that this procedure has a significant global market opportunity of approximately four billion Euros per year for this treatment.

All company activities in Europe are aimed at further increasing awareness of the NanoTherm therapy system and making it available to patients. For example, the MagForce's 'NanoTherm Therapy School', a practice-oriented, unique and versatile application training course for the use of the NanoTherm therapy system for the treatment of glioblastoma, continues to be very successful. The goal of the comprehensive application training is to certify surgeons in the use of our innovative NanoTherm technology. Just this month, the third session, Module B - Part II, in the training was concluded. As seen in the registration numbers and also in participant feedback, interest in MagForce's innovative therapy is greater than ever before.

As part of the Company's European roll-out strategy, further installations of NanoActivator devices in partner hospitals in Spain and Italy are planned. The opening of these additional centers, which were planned for the second half of 2020, will be further delayed due to the enormous impact that the COVID-19 pandemic is unfortunately currently having again in these countries. However, interest from other European countries has been seen and MagForce will continue its roll-out strategy in the coming months. In addition, in Germany, the official opening of the latest NanoTherm therapy center at the Hufeland clinic in Mhlhausen is scheduled for November and, MagForce is planning another NanoTherm treatment center in Germany. All this will help us to achieve the treatment goal for 2021 and triple the number of commercial treatments compared to 2020.

Commercial Model for Brain Cancer Treatments in Europe: 'Plug-and-Treat'

To make the NanoTherm therapy system more assessable to clinics, MagForce has developed a container 'plug-and-treat' solution, which has become the delivery standard in Germany as well as in European countries. The pre-installed containers only require a dedicated outdoor space and a standard three phase current connection and are transported to the clinic by truck. MagForce delivers complete regulatory and technical documentation to the clinic administration in advance so that official approvals can be issued quickly. With this mobile 'plug-and-treat' solution the Company has been able to significantly shorten the time to start patient treatment in new centers. Currently, no more than three months from the date of order placement to commission a new NanoTherm treatment center in Germany or other European countries is expected. MagForce currently still has materials in stock for the new production of three additional devices, which will be manufactured on schedule, if required.

USA - Focal Prostate Cancer Treatment

Mirroring results on the first stage of the focal prostate cancer treatment study, treatment results in the current stage of the study, with the streamlined procedure, show only minimal treatment-related side effects that are tolerable and similar to those of biopsies. The ablation analysis showed a very well-defined ablation and cell death in the area of the nanoparticle depot, as observed in previous preclinical studies. This was expected, but is nevertheless very encouraging, as patients can be treated much faster. It is obvious that the streamlined study protocol will benefit patients by completing the entire treatment within one day, thus minimizing the burden of repeated visits to the treating physician.

We continue to expect to generate sufficient data in the fourth quarter of 2020 to confirm that our streamlined procedure has minimal side effects for patients and to gain the necessary 80 percent confidence to meet the clinical objectives needed for FDA approval. The big challenges that the COVID-19 pandemic poses to the health care system mean for our study, among other things, that for several weeks now every patient has to be tested, undergo a two-week quarantine and then be tested again. This brings an unavoidable delay to the almost completed current Stage 2a of the study, and by now we expect to complete the current stage still this year and start the final Stage 2b in January.

Commercial Model for Focal Cancer Treatment Centers in the U.S.: Lease Back Partnership

While completing the study, MagForce will begin preparations for commercialization, which is still expected to start in mid or second half of 2021. Our three MagForce USA owned and operated locations in San Antonio, Texas; Seattle, Washington; and Sarasota, Florida will be our primary locations. All three participating clinical trial sites are already fully equipped with the NanoActivator devices, a dedicated and trained staff, and would be in a position to start commercial treatments immediately. Upon completion of the study, the Company plans to have two additional proprietary treatment centers in place. Additional sites will then be opened in strategic locations in the U.S. to enable the treatment of patients locally. MagForce is already in contact with the most important "Active Surveillance Programs" throughout the country to evaluate their desire for an ambulatory NanoActivator.

MagForce USA's commercial model considers two marketing channels: 1) stand-alone Focal Cancer Treatment Centers owned and staffed by MagForce USA. This would allow MagForce USA to bill for the entire procedure as it is standard with for example dialysis treatments; 2) placement of ambulatory NanoActivators in urology clinics, providing the NanoTherm therapy system to the respective clinical site. To facilitate either channel, MagForce USA has established a sale and lease back partnership for U.S. NanoActivators with three-year term each. This will allow MagForce USA to accelerate its commercial plan.

Considering the potential global market, over 500,000 prostate cancer patients could be treated per year and benefit from an effective focal treatment with minimal side effects. The market potential would lie between 3.5 and 12.5 billion USD per year depending on the business model.

Results of operations, net assets and financial position

Revenues amounted to EUR 384 thousand, a strong increase compared to EUR 26 thousand in the previous year. The revenues were generated from the commercial treatment of patients with NanoTherm therapy in Germany in the amount of EUR 212 thousand (previous year: EUR 23 thousand) and NanoTherm and catheter deliveries to subsidiaries in the amount of EUR 173 thousand (previous year: EUR 3 thousand). A total of 11 patients were treated at the German centers and 6 patients in Lublin, Poland in the first half of 2020.

Other own work capitalized amounting to EUR 196 thousand (previous year: EUR 0 thousand) relates to capitalized expenses for preparing the product files for MagForce AG's medical products in accordance with the requirements of the new Medical Device Regulation (MDR).

Other operating income amounted to EUR 332 thousand in the reporting period and was largely at the previous year's level (EUR 329 thousand).

Cost of materials increased from EUR 194 thousand to EUR 286 thousand. The cost of raw materials, supplies and purchased goods as well as purchased services increased to the same extent.

Personnel expenses increased to EUR 2,097 thousand (previous year: EUR 1,846 thousand).

At EUR 1,667 thousand, other operating expenses were EUR 59 thousand higher than in the previous year (EUR 1,608 thousand) and were thus largely at the previous year's level.

The operating result for the first half of 2020 was EUR -3,432 thousand (previous year: EUR -3,610 thousand). The strong increase in revenues contributed significantly to the improved result.

While interest income remained constant at EUR 108 thousand (previous year: EUR 108 thousand), interest expenses rose from EUR 949 thousand to EUR 1,030 thousand due to the expansion of external financing. Write-downs on financial assets increased by EUR 61 thousand and amounted to EUR 521 thousand (previous year: EUR 460 thousand) which relates to the contributions made to finance the operating activities of the subsidiary MT MedTech Engineering GmbH.

The first half of 2020 closed with a net loss of EUR -4,877 thousand. Due to the increased revenues, the result for the period improved by EUR 35 thousand compared to the previous year (EUR -4,912 thousand).

Cash flow from operating activities amounted to EUR -2,290 thousand (previous year: EUR -2,856 thousand). The cash outflow from operating activities was derived indirectly from the net loss for the period. The cash outflows mainly relate to the financing of operating activities.

Cash flow from investing activities amounted to EUR -1,850 thousand (previous year: EUR -785 thousand) and primarily related to the contributions made to provide financial support to the subsidiary MT MedTech Engineering GmbH and payments for the construction of mobile NanoActivators as well as the expenses incurred in preparing the technical documentation for MagForce products.

Cash flow from financing activities amounted to EUR 5,653 thousand (previous year: EUR 3,325 thousand) and is mainly attributable to the payments received in connection with the external financing measures implemented. The payments received were in part offset by cash outflows in the form of interest payments.

At the end of the reporting period, the freely available liquidity amounted to EUR 1,680 thousand (December 31, 2019: EUR 167 thousand). The increase is due to the drawing of the second tranche of the EIB loan and the issue of new convertible bonds.

Outlook and financial prognosis 2020 and beyond

The outlook for the year 2020, as reported in the 2019 annual report, published on June 30, 2020 was reaffirmed by management.

About MagForce AG and MagForce USA, Inc.MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

T +49-30-308380-77E-Mail: bfrankenberg@magforce.com

30.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continue reading here:
MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights - PharmiWeb.com

Recommendation and review posted by Alexandra Lee Anderson

SHAREHOLDER ALERT: WeissLaw LLP Reminds HCAC, TOTA, and LFAC Shareholders About Its Ongoing Investigations – PRNewswire

NEW YORK, Oct. 30, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212)682-3025(888) 593-4771[emailprotected]

Hennessy Capital Acquisition Corp. IV (NASDAQ: HCAC)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hennessy Capital Acquisition Corp. IV(NASDAQ: HCAC)in connection with the company's merger with privately-held Canoo Holdings Ltd. ("Canoo"). Under the terms of the proposed transaction, the company will acquire Canoo through a reverse merger that will result in Canoo becoming a publicly-traded company. The deal has a pro forma equity value of approximately $2.4 billion.If you own HCAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/hennessy-capital-acquisition-corp-iv/

Tottenham Acquisition I Limited (NASDAQ: TOTA)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA)in connection with the company's proposed merger with Clene Nanomedicine, Inc. ("Clene"). Under the terms of the agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a publicly-traded company. Additionally,Clene shareholders will be entitled to receive earn-out consideration of up to an additional 8.33 million shares of the newly combined company's common stock, subject to the new company achieving certain milestones. The proposed transaction values Clene at $542.5 million. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

LF Capital Acquisition Corp. (NASDAQ: LFAC)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LF Capital Acquisition Corp. (NASDAQ: LFAC)in connection with the proposed acquisition of Landsea Homes Incorporated ("Landsea Homes"). Under the terms of the acquisition agreement, LFAC will acquire Landsea Homes through a reverse merger that will result in Landsea Homes becoming a publicly-traded company. The combined company is expected to have a pro forma equity value of approximately $510 million. Upon closing, Landsea Homes' founder, Landsea Green Properties Co., Ltd., will own 67.4% of the newly-combined company. If you own LFAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/lf-capital-acquisition-corp/

SOURCE WeissLaw LLP

Home in Elementor

Here is the original post:
SHAREHOLDER ALERT: WeissLaw LLP Reminds HCAC, TOTA, and LFAC Shareholders About Its Ongoing Investigations - PRNewswire

Recommendation and review posted by Alexandra Lee Anderson

New Nanomedicine Approach Could Improve Effectiveness of COVID-19 Vaccine – AZoNano

Written by AZoNanoOct 29 2020

Researchers led by the University at Buffalo (UB) have devised a new method that could enhance the effectiveness of vaccines against the novel coronavirus, the virus that is responsible for causing COVID-19.

Jonathan F. Lovell, PhD, an associate professor in the Department of Biomedical Engineering at UB, is the principal investigator of the study titled SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination, published online in the Advanced Materials journal on October 28th, 2020.

COVID-19 has resulted in an uncontrollable global pandemic, which has infected a minimum of 40 million people around the world and resulted in over 220,000 deaths in the United States alone. As the disease started spreading in early 2020, biomedical researchers have been working actively to develop an effective vaccine.

Lovell thinks that one solution could be to develop vaccines that partly imitate the virus structure. One of the proteins on the virussituated on the characteristic COVID spikeincludes a component known as the receptor-binding domain, or RBD, which is its Achilles heel. Lovell stated that antibodies against this part of the virus have the ability to neutralize the virus.

It would be appealing if a vaccine could induce high-levels of antibodies against the RBD. One way to achieve this goal is to use the RBD protein itself as an antigen, that is, the component of the vaccine that the immune response will be directed against.

Jonathan F. Lovell, Associate Professor, Department of Biomedical Engineering, University at Buffalo

The researchers speculated that if the RBD is transformed into a nanoparticle (similar in size to the virus itself) rather than retaining it in its natural form as a tiny protein, it would produce higher levels of neutralizing antibodies and its potential to produce an immune response would increase.

Earlier, Lovells group had designed a technology that enables the simple transformation of small, purified proteins into particles by using liposomes, or small nanoparticles developed from naturally occurring fatty components.

In the latest study, the team added a unique lipid known as cobalt-porphyrin-phospholipid or CoPoP inside the liposomes. The lipid allows the RBD protein to quickly bind to the liposomes, developing more nanoparticles that produce an immune response, stated Lovell.

The researchers noticed that when the RBD was transformed into nanoparticles, it retained its correct, three-dimensional shape and the particles were stable in incubation conditions, analogous to those present in the human body.

High antibody levels were induced in laboratory rabbits and mice immunized with the RBD particles. When compared to other materials integrated with the RBD to improve the immune response, only the method with particles containing CoPoP ensured a powerful response.

According to Lovell, other vaccine adjuvant technologies cannot transform the RBD into particle-form.

We think these results provide evidence to the vaccine-development community that the RBD antigen benefits a lot from being in particle format. This could help inform future vaccine design that targets this specific antigen.

Jonathan F. Lovell, Associate Professor, Department of Biomedical Engineering, University at Buffalo

This research was funded by the U.S. National Institutes of Health, and the Facility for Electron Microscopy Research (FEMR) at McGill University. FEMR is supported by the Canadian Foundation for Innovation, Quebec Government, and McGill University.

Huang, W.-C., et al. (2020) SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination. Advanced Materials. doi.org/10.1002/adma.202005637.

Source: http://www.buffalo.edu/

Original post:
New Nanomedicine Approach Could Improve Effectiveness of COVID-19 Vaccine - AZoNano

Recommendation and review posted by Alexandra Lee Anderson

Healthcare Nanotechnology (Nanomedicine) Market 2020 with Growth, Share, Demand, Global Production with Revenue Share, and Applications Forecast to…

Healthcare Nanotechnology (Nanomedicine) Market report delivers an overview of the market trends, drivers, and barriers with respect to the competitive landscape. It also provides a detailed overview of the market of different regions globally.Furthermore, the Healthcare Nanotechnology (Nanomedicine) market report contains a primary overview of the Healthcare Nanotechnology (Nanomedicine) market covering different product definitions, classifications, and participants in the industry chain structure.

The global Healthcare Nanotechnology (Nanomedicine) market provides quantitative and qualitative analysis of the competitive landscape, development trends, and key success in the Healthcare Nanotechnology (Nanomedicine) industry.

Competitor Landscape: Healthcare Nanotechnology (Nanomedicine) market report contains top companies on the basis of types, applications, size, share, and regions.

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Reason to buy Healthcare Nanotechnology (Nanomedicine) Market Report:

Purchase this Report (Price 4250 USD for a Single-User License) https://www.industryresearch.co/purchase/14099195

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Hyoscine-N-Butyl Bromide Market Size and Share Outlook 2020 to 2026 | Key Developments Trends, Growth Factors, Business Status and Regional Analysis

Property Management System in Hotel Market Growth Share 2020 Regional Trends, Market Overview with Key Players, Industry Size, Demand Status Forecast to 2025 | Report by Industry Research.co

Wood Ceilings Market Share and Business Development 2020 Future Plans of Top Companies, Growth Size, Industry Share by Latest Trends Forecast to 2025

PBT Engineering Plastics Market Growth Opportunities by Key Players 2020 | Evolving Technologies, Market Dynamics, Global Size, Industry Share Analysis till 2026 Report by Industry Research.co

Ethylene Methacrylic Acid (EMA) Market Size, Share, Top Manufacturers 2020 Future Growth Rate, Industry Trends, Business Strategy, Demand Status by 2026 With COVID-19 Analysis

Rangefinders Market Growth Factors by Latest Developments 2020 | Future Demand Status, Business Strategies, Opportunities, Trends, Industry Size and Share Forecast to 2026

IVF Devices and Consumables Market 2020 | by Growing Factors, Size, Global Opportunities by Leading Players, Top Countries Data, Demand Status, Regional Overview by CAGR Value, and Share Analysis till 2026

Dental Carts Market Size Analysis by Latest Trends 2020 | Global Industry Growth Factors, Revenue, CAGR Status, Leading Key Players Update, Business Share by Regions Forecast to 2026

Epigenetics Drugs and Diagnostic Technologies Market Size by Growth Scenario 2020 Trend Analysis, Industry Status by Manufacturers, Business Share, Future Scope and Global Opportunities Forecast to 2026

Deep Brain Stimulation (DBS) Devices Market Size, Share Analysis 2020 Global Analysis by Key Players, Growth Overview, Type and Applications by Regions Forecast to 2025 | Industry Research.co

Cholesterol Lowering Biologic Drugs Market Size by Future Scope 2020 | Global Industry Revenue, Share, Future Demand Status, Growth Segmentations Analysis by Regions Forecast to 2026

Beeswax Market Growth Share 2020 Regional Trends, Market Overview with Key Players, Industry Size, Demand Status Forecast to 2025 | Report by Industry Research.co

Read the rest here:
Healthcare Nanotechnology (Nanomedicine) Market 2020 with Growth, Share, Demand, Global Production with Revenue Share, and Applications Forecast to...

Recommendation and review posted by Alexandra Lee Anderson

Transforming coronavirus protein into a nanoparticle could be key to effective COVID-19 vaccine – UB Now: News and views for UB faculty and staff -…

A UB-led research team has discovered a technique that could help increase the effectiveness of vaccines against the novel coronavirus, the virus that causes COVID-19.

Jonathan F. Lovell, associate professor in the Department of Biomedical Engineering, is the primary investigator on the research, titled SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination, which was published online today in Advanced Materials.

COVID-19 has caused a disruptive global pandemic, infecting at least 40 million worldwide and causing more than 220,000 deaths in the United States alone. Since it began spreading in early 2020, biomedical researchers have been in active pursuit of an effective vaccine.

According to Lovell, one answer might lie in designing vaccines that partially mimic the structure of the virus. One of the proteins on the virus located on the characteristic COVID spike has a component called the receptor-binding domain, or RBD, which is its Achilles heel. That is,he says, antibodies against this part of the virus have the potential to neutralize the virus.

It would be appealing if a vaccine could induce high levels of antibodies against the RBD, Lovell says. One way to achieve this goal is to use the RBD protein itself as an antigen; that is, the component of the vaccine that the immune response will be directed against.

The team hypothesized that by converting the RBD into a nanoparticle (similar in size to the virus itself) instead of letting it remain in its natural form as a small protein, it would generate higher levels of neutralizing antibodies and its ability to generate an immune response would increase.

Lovells team had previously developed a technology that makes it easy to convert small, purified proteins into particles through the use of liposomes, or small nanoparticles formed from naturally occurring fatty components. In the new study, the researchers included within the liposomes a special lipid called cobalt-porphyrin-phospholipid, or CoPoP. That special lipid enables the RBD protein to rapidly bind to the liposomes,forming more nanoparticles that generate an immune response, Lovell explains.The team observed that when the RBD was converted into nanoparticles, it maintained its correct, three-dimensional shape and the particles were stable in incubation conditions similar to those in the human body. When laboratory mice and rabbits were immunized with the RBD particles, high antibody levels were induced. Compared to other materials that are combined with the RBD to enhance the immune response, only the approach with particles containing CoPoP gave strong responses.

Other vaccine adjuvant technology does not have the capacity to convert the RBD into particle-form, Lovell notes.

We think these results provide evidence to the vaccine-development community that the RBD antigen benefits a lot from being inparticle format, he says. This could help inform future vaccine design that targets this specific antigen.

Lovells co-authors on the study include Wei-Chiao Huang, Shiqi Zhou, Xuedan He and Moustafa T. Mabrouk, all from the UB Department of Biomedical Engineering; Kevin Chiem and Luis Martinez-Sobrido, both from Texas Biomedical Research Institute; Ruth H. Nissly, Ian M. Bird and Suresh V. Kuchipudi, all from the Animal Diagnostic Laboratory, Department of Veterinary and Biomedical Sciences at Pennsylvania State University; Mike Strauss and Joaquin Ortega from the Department of Anatomy and Cell Biology at McGill University; Suryaprakash Sambhara from the Immunology and Pathogenesis Branch of the U.S. Centers for Disease Control and Prevention; Elizabeth A. Wohlfert from the UB Department of Microbiology and Immunology; and Bruce A. Davidson from the Department of Anesthesiology and the Department of Pathology and Anatomical Sciences at UB.

Lovell founded the Lovell Lab at UB in 2012. It is focused on developing novel nanomedicine approaches to meet unmet needs in treating and preventing disease. He is also a co-founder of POP Biotechnologies Inc., a preclinical stage biotechnology company developing next-generation drug and vaccines products.

The study was supported by the U.S. National Institutes of Health and the Facility for Electron Microscopy Research (FEMR) at McGill University. FEMR is supported by the Canadian Foundation for Innovation, Quebec Government and McGill.

Read the original:
Transforming coronavirus protein into a nanoparticle could be key to effective COVID-19 vaccine - UB Now: News and views for UB faculty and staff -...

Recommendation and review posted by Alexandra Lee Anderson

Increase in the Adoption of Healthcare Nanotechnology (Nanomedicine) to Propel the Growth of the Healthcare Nanotechnology (Nanomedicine) Market…

This report presents the worldwide Healthcare Nanotechnology (Nanomedicine) market size (value, production and consumption), splits the breakdown (data status 2018 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Top Companies in the Global Healthcare Nanotechnology (Nanomedicine) Market:

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

The report provides a valuable source of insightful data for business strategists and competitive analysis of Healthcare Nanotechnology (Nanomedicine) Market. It provides the Healthcare Nanotechnology (Nanomedicine) industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Healthcare Nanotechnology (Nanomedicine) study provides comprehensive data which enhances the understanding, scope and application of this report.

Influence of the Healthcare Nanotechnology (Nanomedicine) market report:

-Comprehensive assessment of all opportunities and risk in the Healthcare Nanotechnology (Nanomedicine) market.

Healthcare Nanotechnology (Nanomedicine) market recent innovations and major events.

-Detailed study of business strategies for growth of the Healthcare Nanotechnology (Nanomedicine) market-leading players.

-Conclusive study about the growth plot of Healthcare Nanotechnology (Nanomedicine) market for forthcoming years.

-In-depth understanding of Healthcare Nanotechnology (Nanomedicine) market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Healthcare Nanotechnology (Nanomedicine) market.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

The report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 Healthcare Nanotechnology (Nanomedicine) Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Type

1.4.2 Hydraulic Dredges

1.4.3 Hopper Dredges

1.4.4 Mechanical Dredges

1.5 Market by Application

1.5.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Application

2 Executive Summary

2.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size

2.1.1 Global Healthcare Nanotechnology (Nanomedicine) Revenue 2014-2025

2.1.2 Global Healthcare Nanotechnology (Nanomedicine) Production 2014-2025

2.2 Healthcare Nanotechnology (Nanomedicine) Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key Healthcare Nanotechnology (Nanomedicine) Manufacturers

2.3.2.1 Healthcare Nanotechnology (Nanomedicine) Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Healthcare Nanotechnology (Nanomedicine) Product Offered

2.3.2.3 Date of Manufacturers Enter into Healthcare Nanotechnology (Nanomedicine) Market

2.4 Key Trends for Healthcare Nanotechnology (Nanomedicine) Markets & Products

3 Market Size by Manufacturers

3.1 Healthcare Nanotechnology (Nanomedicine) Production by Manufacturers

3.1.1 Healthcare Nanotechnology (Nanomedicine) Production by Manufacturers

3.1.2 Healthcare Nanotechnology (Nanomedicine) Production Market Share by Manufacturers

3.2 Healthcare Nanotechnology (Nanomedicine) Revenue by Manufacturers

3.2.1 Healthcare Nanotechnology (Nanomedicine) Revenue by Manufacturers (2019-2025)

3.2.2 Healthcare Nanotechnology (Nanomedicine) Revenue Share by Manufacturers (2019-2025)

3.3 Healthcare Nanotechnology (Nanomedicine) Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

See the rest here:
Increase in the Adoption of Healthcare Nanotechnology (Nanomedicine) to Propel the Growth of the Healthcare Nanotechnology (Nanomedicine) Market...

Recommendation and review posted by Alexandra Lee Anderson


Page 10«..9101112..2030..»